EXCLUSIVE LICENSE AGREEMENT FOR CK1d by and between AMGEN INC. and RBNC Therapeutics, Inc. Dated as of September 10, 2021Exclusive License Agreement for Ck1d • August 25th, 2023 • Neumora Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
This EXCLUSIVE LICENSE AGREEMENT FOR CK1d (this “Agreement”) is entered into as of September 10, 2021 (the “Execution Date”) by and between AMGEN INC. (“AMGEN”), and RBNC Therapeutics, Inc. (“RBNC”). RBNC and AMGEN are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
